Lisaftoclax
Acute Promyelocytic Leukemia
The Affiliated People's Hospital of Ningbo UniversitySmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Acute Promyelocytic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tretinoin The Affiliated People's Hospital of Ningbo University | Phase 4 | A |
CYTARABINE Associazione Italiana Ematologia Oncologia Pediatrica | Phase 4 | A |
Idarubicin Technische Universität Dresden | Phase 4 | A |
Arsenic Trioxide Quetzal Therapeutics | Phase 4 | BBB |
Mitoxantrone Technische Universität Dresden | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Lisaftoclax is also rated in:
chronic lymphocytic leukemia/small lymphocytic lymphomaActive
BBB
Indicative · Phase 3
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →